What is NVS's health score?

NOVARTIS AG (NVS) has a TradeApes health score of 69 out of 100, rated Healthy. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is NVS's estimated fair value?

Based on our 5-year discounted cash flow model, NOVARTIS AG's estimated fair value is $254.63 per share, representing a 72.5% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is NVS undervalued or overvalued?

Our model currently rates NVS as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for NVS... Refresh in a moment for the full analysis.

NOVARTIS AG (NVS)

Healthcare Undervalued medium healthy

$147.65

Updated: 2026-06-04

TradeApes Score

Financial Strength

70 Healthy

Operating Trend

71 Healthy

Relative Value

75 Strong

Capital Allocation

55 Mixed

Risk

70 Healthy

Est. Fair Value $254.63

DCF Upside +72.5%

Sector Rank #1882 of 6917

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− High P/E — 25–45×, growth premium already priced in

Unlock Full Report →

4 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.